Latest Articles

  • Irritable bowel syndrome with diarrhea: Treatment is a work in progress
    Michael Kurin, MD and Gregory Cooper, MD
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 501-511; DOI: https://doi.org/10.3949/ccjm.87a.19011

    Understanding of its mechanisms is progressing, and treatments are increasingly targeted to the individual etiology.

  • Coagulopathy in COVID-19: Manifestations and management
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 461-468; DOI: https://doi.org/10.3949/ccjm.87a.ccc024

    Prophylaxis against venous thromboembolism is recommended for all patients hospitalized with COVID-19.

  • In Reply: Aspirin for primary prevention
    Aldo L. Schenone, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine August 2020, 87 (8) 458-459; DOI: https://doi.org/10.3949/ccjm.87c.08006
  • Does a short QT interval increase the risk of cardiac death in healthy people?
    Ahmed Subahi, MD, Ahmed S. Yassin, MD, Oluwole Adegbala, MD, Mohamed Shokr, MD and Luis Afonso, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 398-400; DOI: https://doi.org/10.3949/ccjm.87a.19090

    No, but it may warrant further investigation to determine if the patient is at risk.

  • Cytokines and the still-baffling clinical biology of COVID-19
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 381-382; DOI: https://doi.org/10.3949/ccjm.87b.07020

    The primary culprit is not certain. Is it all immune damage, or is the continued persistence of coronavirus playing a role?

  • Cytokine storm and the prospects for immunotherapy with COVID-19
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 389-393; DOI: https://doi.org/10.3949/ccjm.87a.ccc008

    Despite gaping holes in our knowledge, treatment is evolving.

  • Glucocorticoid-induced osteoporosis: Insights for the clinician
    Shakaib Hayat, MD and Marina N. Magrey, MD
    Cleveland Clinic Journal of Medicine July 2020, 87 (7) 417-426; DOI: https://doi.org/10.3949/ccjm.87a.19039

    Glucocorticoids cause significant bone loss, predominantly affecting trabecular bone, with consequent fragility fractures.

  • Denosumab cessation
    Chad L. Deal, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 339-341; DOI: https://doi.org/10.3949/ccjm.87a.20040

    Bone loss is rapid if patients miss injections. Clinicians can take extra measures to ensure patients get appropriate treatment.

  • Vertebral fractures after denosumab cessation
    Jolan Dupont, MD, Michaël R. Laurent, MD,PhD, Lenore Dedeyne, MSc, Frank P. Luyten, MD,PhD, Evelien Gielen, MD,PhD and Marian Dejaeger, MD,PhD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 337-338; DOI: https://doi.org/10.3949/ccjm.87a.19152

    The patient had a 6-month history of lumbar and dorsal back pain, initially suspected to be facet arthrosis.

  • Recurrent Clostridioides difficile infection: Recognition, management, prevention
    Constantine Tsigrelis, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 347-359; DOI: https://doi.org/10.3949/ccjm.87gr.20001

Pages